fazarabine has been researched along with Neoplasms in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (25.00) | 18.7374 |
1990's | 6 (75.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bernstein, ML; Devine, S; Dubowy, R; Grier, H; Kung, F; Land, V; Murphy, S; Whitehead, VM | 1 |
Ames, MM; Erlichman, C; Fitch, TR; Goldberg, RM; Kuffel, MJ; Reid, JM; Rubin, J; Sloan, JA | 1 |
Amato, R; Ho, D; Krakoff, IH; Raber, M; Schmidt, S | 1 |
Ben-Baruch, N; Cowan, KH; Fine, R; Ford, H; Kelley, JA; Surbone, A; Thomas, RV | 1 |
Alberti, D; Arzoomanian, RZ; Bailey, H; Bruggink, J; Tombes, MB; Tutsch, KD; Wilding, G | 1 |
Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
Balis, FM; Ettinger, LJ; Ford, H; Gillespie, A; Heideman, RL; Packer, RJ; Poplack, DG; Reaman, GH; Sato, J; Tan, C | 1 |
Durr, FE; Lindh, D; Wallace, RE | 1 |
1 review(s) available for fazarabine and Neoplasms
Article | Year |
---|---|
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
5 trial(s) available for fazarabine and Neoplasms
Article | Year |
---|---|
A phase I trial of fazarabine in refractory pediatric solid tumors. A Pediatric Oncology Group study.
Topics: Antineoplastic Agents; Azacitidine; Child; Child, Preschool; Drug Administration Schedule; Humans; Neoplasms | 1993 |
Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Topics: Adult; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Metabolic Clearance Rate; Nausea; Neoplasms; Neutropenia | 1997 |
Phase I trial of a 72-h continuous-infusion schedule of fazarabine.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Drug Administration Schedule; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1992 |
Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 1990 |
Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Azacitidine; Dose-Response Relationship, Drug; Humans; Infusions, Intravenous; Metabolic Clearance Rate; Middle Aged; Neoplasms | 1991 |
2 other study(ies) available for fazarabine and Neoplasms
Article | Year |
---|---|
Phase I trial and pharmacokinetic evaluation of fazarabine in children.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Child; Drug Evaluation; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Neoplasms | 1989 |
Arabinofuranosyl-5-azacytosine: activity against human tumors in athymic mice.
Topics: Animals; Antineoplastic Agents; Azacitidine; Cell Transformation, Neoplastic; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Stereoisomerism; Time Factors; Transplantation, Heterologous; Tumor Cells, Cultured | 1989 |